Condition: Non-muscle-invasive Bladder Cancer · Sponsor: SURGE Therapeutics
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
This description comes directly from the study's public registry record.
Kayti Aviano · 781-605-8632 · kayti@surgetx.com
Always discuss trial participation with your own doctor first.
| East Valley Urology Center of Arizona | Mesa, Arizona, United States | Recruiting |
| Arizona Urology Specialists | Tucson, Arizona, United States | Completed |
| Arkansas Urology | Little Rock, Arkansas, United States | Recruiting |
| Unio Specialty Care - A Genesis Healthcare Partners Facility | Bakersfield, California, United States | Recruiting |
| Genesis Research | Downey, California, United States | Recruiting |
| Urology Center of Southern California | Murrieta, California, United States | Recruiting |
| Advanced Urology Institute | Daytona Beach, Florida, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Advent Health | Orlando, Florida, United States | Recruiting |
| Anna Arundel Urology | Annapolis, Maryland, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| Michigan Institute of Urology | Troy, Michigan, United States | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05710848